Vaxcyte Inc.’s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
Trending News
November 5, 2024
November 5, 2024
November 5, 2024
November 4, 2024